H.C. Wainwright analyst Robert Burns downgraded Y-mAbs Therapeutics (YMAB) to Neutral from Buy with a price target of $8.60, down from $11, after the company entered into a merger agreement under which Serb will acquire Y-mAbs for $8.60 per share. The firm does not expect rival bidders to emerge.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
- Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
- Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics
- Y-mAbs Therapeutics downgraded to Hold from Buy at Truist